Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 07, 2024 07:05 ET | uniQure Inc.
uniQure announces first quarter 2024 results
Apellis logo.jpg
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024 07:05 ET | Apellis Pharmaceuticals, Inc.
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) ...
eledon-logo-1230.png
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 07, 2024 07:05 ET | Eledon Pharmaceuticals, Inc.
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
tjc_logo_reverse.jpg
The Joint Corp. to Participate in Upcoming Investor Conferences
May 07, 2024 07:05 ET | The Joint Corp.
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation’s largest provider of chiropractic care through The Joint Chiropractic® network, announced that...
Gilat Logo Full Color.png
SES’s O3b mPOWER System Launches Service via Gilat’s SkyEdge IV Platform
May 07, 2024 07:03 ET | Gilat Satellite Networks Ltd.
PETAH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services,...
ptx-logo .png
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:01 ET | Prelude Therapeutics, Inc.
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024  New preclinical data presented at...
FirstWatchLogo_Horiz_K (002).png
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Results
May 07, 2024 07:00 ET | First Watch Restaurant Group, Inc.
Total revenues increased 14.7%; same-restaurant sales growth of 0.5%*Income from operations margin of 5.1% and restaurant level operating profit margin of 20.8%Net income of $7.2 million and Adjusted...
BioCryst_PrimaryLogo_R_2C_RGB.jpg
BioCryst to Present at Upcoming Investor Conferences
May 07, 2024 07:00 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences: Citizens JMP...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
May 07, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around...
arvinas_logoART_lg.jpg
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:00 ET | Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...